Wendy I. White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wendy I. White has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alexander MacDonald
Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK
1 shared publicationDavid W. Boulton
Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, USA
1 shared publication- Joachim Almquist
Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
1 shared publication L. Wang
AstraZeneca, Gaithersburg, USA
1 shared publicationL.K. Roskos
MedImmune
1 shared publication- Michael S. Hwang
26AstraZeneca, South San Francisco, California
1 shared publication
Latest Publications
- Open Access
- 6 May 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (5) , 655-671
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving standard therapy. The approved dosing regimen of anifrolumab is a 300-mg dose administered intravenously every 4 weeks; this was initially based on the results of the Phase 2b MUSE and further confirmed in the Phase 3 TULIP-1 and TULIP-2 trials, in which anifrolumab 300-mg treatment was associated with clinically meaningful improvements in disease activity with an acceptable safety profile. There have been several published analyses of the pharmacokinetic and pharmacodynamic profile of anifrolumab, including a population–pharmacokinetic analysis of 5 clinical studies of healthy volunteers and patients with SLE, in which body weight and type I IFN gene expression were significant covariates identified for anifrolumab exposure and clearance. Additionally, the pooled Phase 3 SLE population has been used to evaluate how serum exposure may be related to clinical responses, safety risks, and pharmacodynamic effects of the 21-gene type I IFN gene signature (21-IFNGS). The relevance of 21-IFNGS with regard to clinical efficacy outcomes has also been analyzed. Herein, the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab as well as results of population–pharmacokinetics and exposure–response analyses are reviewed.
- 6 May 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (5) , 655-671
Open AccessClinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving standard therapy. The approved dosing regimen of anifrolumab is a 300-mg dose administered intravenously every 4 weeks; this was initially based on the results of the Phase 2b MUSE and further confirmed in the Phase 3 TULIP-1 and TULIP-2 trials, in which anifrolumab 300-mg treatment was associated with clinically meaningful improvements in disease activity with an acceptable safety profile. There have been several published analyses of the pharmacokinetic and pharmacodynamic profile of anifrolumab, including a population–pharmacokinetic analysis of 5 clinical studies of healthy volunteers and patients with SLE, in which body weight and type I IFN gene expression were significant covariates identified for anifrolumab exposure and clearance. Additionally, the pooled Phase 3 SLE population has been used to evaluate how serum exposure may be related to clinical responses, safety risks, and pharmacodynamic effects of the 21-gene type I IFN gene signature (21-IFNGS). The relevance of 21-IFNGS with regard to clinical efficacy outcomes has also been analyzed. Herein, the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab as well as results of population–pharmacokinetics and exposure–response analyses are reviewed.
- Open Access
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 668
FRI0256 Effects of anifrolumab on oxidative stress and macrophage activation: novel biomarkers and impact of type i interferon blockade in systemic lupus erythematosus
Background Type I interferons (IFNs) drive several aspects of systemic lupus erythematosus (SLE) etiology and pathophysiology. Anifrolumab, a fully human anti-IFN-α receptor monoclonal antibody, substantially reduced disease activity compared with placebo in a Phase IIb study of SLE patients.1 Previous results indicated beneficial effects of anifrolumab on dysregulated lymphocyte, neutrophil, and complement systems in SLE.2 However, the impact of type I IFN blockade remains to be fully elucidated. Objectives We characterised biomarkers for oxidative stress and macrophage activation in SLE and assessed downstream effects of anifrolumab on those two key disease pathways. Methods In the MUSE study,1 305 patients with moderate to severe SLE were randomised in a 1:1:1 ratio to receive placebo or anifrolumab (300 or 1,000 mg) every 4 weeks for 48 weeks. A four-gene expression assay was used to define type I IFN gene signature (IFNGS) test status. In our study, four protein biomarkers were measured in sera of healthy controls (HCs) and SLE patients with samples available at baseline, and 85, 169, and 365 days after administration, using a multiplex luminex immunoassay. Wilcoxon rank-sum test was used to evaluate baseline protein concentrations and posttreatment changes between different groups. Results Two oxidative stress biomarkers, peroxiredoxin 4 (PRDX4) and aldose reductase (AKR1B1), were found in greater serum concentrations in 195 SLE patients than in 20 HCs (pConclusions Our results identified PRDX4 as an oxidative stress marker and FOLR3 as a macrophage activation marker associated with disease activities and type I IFNGS test status in SLE. Anifrolumab administration elicits reduced oxidative stress and decreased monocyte/macrophage activation, which may contribute to the clinical efficacy of anifrolumab in SLE patients. References [1] Furie R, et al. Arthritis Rheumatol. 2017;69:376–86. [2] Guo X, et al. Ann. Rheum. Dis. 2016;75:118. Disclosure of Interest X. Guo Shareholder of: AstraZeneca, Employee of: MedImmune, S. Wang Shareholder of: AstraZeneca, Employee of: MedImmune, L. Wang Shareholder of: AstraZeneca, Employee of: AstraZeneca, L. Roskos Shareholder of: AstraZeneca, Employee of: AstraZeneca, W. White Shareholder of: AstraZeneca, Employee of: MedImmune
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 668
Open AccessFRI0256 Effects of anifrolumab on oxidative stress and macrophage activation: novel biomarkers and impact of type i interferon blockade in systemic lupus erythematosus
Background Type I interferons (IFNs) drive several aspects of systemic lupus erythematosus (SLE) etiology and pathophysiology. Anifrolumab, a fully human anti-IFN-α receptor monoclonal antibody, substantially reduced disease activity compared with placebo in a Phase IIb study of SLE patients.1 Previous results indicated beneficial effects of anifrolumab on dysregulated lymphocyte, neutrophil, and complement systems in SLE.2 However, the impact of type I IFN blockade remains to be fully elucidated. Objectives We characterised biomarkers for oxidative stress and macrophage activation in SLE and assessed downstream effects of anifrolumab on those two key disease pathways. Methods In the MUSE study,1 305 patients with moderate to severe SLE were randomised in a 1:1:1 ratio to receive placebo or anifrolumab (300 or 1,000 mg) every 4 weeks for 48 weeks. A four-gene expression assay was used to define type I IFN gene signature (IFNGS) test status. In our study, four protein biomarkers were measured in sera of healthy controls (HCs) and SLE patients with samples available at baseline, and 85, 169, and 365 days after administration, using a multiplex luminex immunoassay. Wilcoxon rank-sum test was used to evaluate baseline protein concentrations and posttreatment changes between different groups. Results Two oxidative stress biomarkers, peroxiredoxin 4 (PRDX4) and aldose reductase (AKR1B1), were found in greater serum concentrations in 195 SLE patients than in 20 HCs (pConclusions Our results identified PRDX4 as an oxidative stress marker and FOLR3 as a macrophage activation marker associated with disease activities and type I IFNGS test status in SLE. Anifrolumab administration elicits reduced oxidative stress and decreased monocyte/macrophage activation, which may contribute to the clinical efficacy of anifrolumab in SLE patients. References [1] Furie R, et al. Arthritis Rheumatol. 2017;69:376–86. [2] Guo X, et al. Ann. Rheum. Dis. 2016;75:118. Disclosure of Interest X. Guo Shareholder of: AstraZeneca, Employee of: MedImmune, S. Wang Shareholder of: AstraZeneca, Employee of: MedImmune, L. Wang Shareholder of: AstraZeneca, Employee of: AstraZeneca, L. Roskos Shareholder of: AstraZeneca, Employee of: AstraZeneca, W. White Shareholder of: AstraZeneca, Employee of: MedImmune